Retatrutide 10 mg

A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors—currently in advanced clinical trials for obesity and metabolic disorders. It’s being studied for its potent effects on appetite regulation, insulin sensitivity, and lipid metabolism.